Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis

View at publisher
Authors: Toshihiro Ide, Masaaki Yoshikawa, Kohei Suzuyama, Satoru Yagi, Soma Furukawa, Yuki Fukami, Masahisa Katsuno, Haruki Koike
Cited by: 1
References: 43

Abstract

Background In hereditary transthyretin (ATTRv) amyloidosis, axonal neuropathy is the main pathologic basis of polyneuropathy. However, whether nerve conduction slowing resembling chronic inflammatory demyelinating polyneuropathy (CIDP), observed in some patients, reflects primary demyelination or secondary changes related to axonal damage remains unclear.Methods Electrophysiologic findings were compared between 96 patients with V30M ATTRv amyloidosis from nonendemic areas and 175 patients with nutritional or alcoholic axonal neuropathies. Myelinated fiber density was assessed in sural nerve biopsy specimens from 66 and 133 patients, respectively.Results Motor nerve conduction velocity (MCV) was reduced and distal motor latency (DML) was prolonged in both groups compared with normal controls, with more marked changes in ATTRv amyloidosis. Compound muscle action potential (CMAP) amplitude and myelinated fiber density were significantly lower in ATTRv amyloidosis than in nutritional/alcoholic neuropathies (p < 0.001). Conduction slowing fulfilling EAN/PNS CIDP criteria was observed only in patients with severe axonal loss. After adjusting for age, disease duration, and CMAP amplitude, only MCV slowing and DML prolongation in median nerve remained more pronounced in ATTRv amyloidosis.Conclusions CIDP-like conduction slowing in ATTRv amyloidosis largely represents secondary changes caused by axonal degeneration, although additional mechanisms may contribute to slowing in the median nerve.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Alzheimer's disease research and treatments Skin and Cellular Biology Research

Publication details

Journal / source
Amyloid
Publisher
Informa UK Limited
Volume
33
Issue
2
Pages
196–204
Publication date
12 January 2026
Language
EN